Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 348 entries
View as:

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Phase: N/A Priority: Normal
NCT ID: NCT03691974 Org: User:
Start: 10/15/18 End: 01/07/21 Due: 01/07/22

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02958436 Org: User:
Start: 08/31/16 End: 10/03/17 Due: 10/03/18

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06848088 Org: User:
Start: 04/14/25 End: 10/10/29 Due: 10/10/30

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT02395133 Org: User:
Start: 03/25/15 End: 10/18/16 Due: 10/18/17

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04373083 Org: User:
Start: 11/15/20 End: 02/20/25 Due: 02/20/26

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Phase: N/A Priority: Normal
NCT ID: NCT06369467 Org: User:
Start: 05/17/24 End: 03/28/28 Due: 03/28/29

Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD

Phase: N/A Priority: Normal
NCT ID: NCT00527423 Org: User:
Start: 08/31/07 End: 10/31/11 Due: 10/31/12

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT00964795 Org: User:
Start: 12/31/09 End: 08/31/13 Due: 08/31/14

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Phase: N/A Priority: Normal
NCT ID: NCT02999711 Org: User:
Start: 02/03/17 End: 09/10/18 Due: 09/10/19

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00083213 Org: User:
Start: 01/31/04 End: - Due: -

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Phase: N/A Priority: Normal
NCT ID: NCT04209634 Org: User:
Start: 01/27/20 End: 05/02/24 Due: 05/02/25

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04425629 Org: User:
Start: 06/16/20 End: 06/09/22 Due: 06/09/23

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Phase: N/A Priority: Normal
NCT ID: NCT01576484 Org: User:
Start: 02/28/12 End: 12/22/16 Due: 12/22/17

A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations

Phase: N/A Priority: Normal
NCT ID: NCT06019481 Org: User:
Start: 06/30/25 End: 06/30/30 Due: 06/30/31

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06091865 Org: User:
Start: 12/13/23 End: 04/30/29 Due: 04/30/30

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Phase: N/A Priority: Normal
NCT ID: NCT06384820 Org: User:
Start: 11/14/24 End: 05/06/30 Due: 05/06/31

A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06452771 Org: User:
Start: 06/27/24 End: 09/30/25 Due: 09/30/26

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT02418754 Org: User:
Start: 05/05/15 End: 04/03/17 Due: 04/03/18

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Phase: N/A Priority: Normal
NCT ID: NCT04452318 Org: User:
Start: 07/13/20 End: 10/04/21 Due: 10/04/22

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Phase: N/A Priority: Normal
NCT ID: NCT04959448 Org: User:
Start: 08/12/21 End: 07/25/27 Due: 07/25/28

CemiplimAb Survivorship Epidemiology

Phase: N/A Priority: Normal
NCT ID: NCT03836105 Org: User:
Start: 06/27/19 End: 10/28/25 Due: 10/28/26

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Phase: N/A Priority: Normal
NCT ID: NCT02943239 Org: User:
Start: 12/08/16 End: 04/30/19 Due: 04/30/20

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

Phase: N/A Priority: Normal
NCT ID: NCT05081388 Org: User:
Start: 11/08/21 End: 06/30/22 Due: 06/30/23

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT04233918 Org: User:
Start: 06/29/20 End: 05/30/23 Due: 05/30/24

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04982224 Org: User:
Start: 11/09/21 End: 10/23/27 Due: 10/23/28